Q3 Earnings Forecast for ATNM Issued By Zacks Research

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Analysts at Zacks Research issued their Q3 2026 EPS estimates for shares of Actinium Pharmaceuticals in a report issued on Tuesday, September 15th. Zacks Research analyst J. Vandermosten anticipates that the company will post earnings of ($0.22) per share for the quarter. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. Zacks Research also issued estimates for Actinium Pharmaceuticals’ Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at $0.25 EPS, FY2027 earnings at ($0.65) EPS and FY2028 earnings at ($0.62) EPS.

Actinium Pharmaceuticals Stock Down 0.8%

NYSE:ATNM opened at $1.24 on Thursday. Actinium Pharmaceuticals has a 52 week low of $0.74 and a 52 week high of $1.74. The stock’s 50-day moving average price is $0.98 and its 200-day moving average price is $1.08. The stock has a market capitalization of $38.99 million, a PE ratio of -0.89 and a beta of 0.05.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Compass Financial Management LLC purchased a new stake in shares of Actinium Pharmaceuticals during the second quarter worth $588,000. BlackRock Inc. purchased a new stake in Actinium Pharmaceuticals during the 2nd quarter valued at about $388,000. Finally, Renaissance Technologies LLC grew its stake in Actinium Pharmaceuticals by 20.7% during the 1st quarter. Renaissance Technologies LLC now owns 471,600 shares of the company’s stock valued at $469,000 after acquiring an additional 80,816 shares in the last quarter. 27.50% of the stock is owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.